Pharmaxis is a leader in mechanism-based inhibitors of amine oxidases. It has a proven ability to deliver Phase 2 trial ready compounds and an exciting pipeline of drug candidates for valuable targets. Its management team has the long standing expertise in the preclinical, early and late phase clinical trials required to secure successful drug development, as well as the strong industry relationships to deliver global transactions with major pharmaceutical partners.
Pharmaxis' research efforts are focused on discovering new drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from the Company's world leading, proprietary amine oxidase inhibitor chemistry platform.
The Company’s strategy is to develop drugs to phase 1 or phase 2, depending upon the targeted disease and then seek to licence drugs to a large pharmaceutical company.
The first products from the Company’s amine oxidase platform have been inhibitors of the enzymes Semicarbazide-Sensitive Amine Oxidase (SSAO) and Lysyl Oxidase-Like type 2 (LOXL2). Both of these enzymes are involved in the inflammatory and fibrotic progression of numerous serious chronic diseases.
In May 2015 Pharmaxis sold its anti-inflammatory drug candidate BI 1467335 (formerly known as PXS-4728A), the first drug developed from the amine oxidase platform, to leading global pharmaceutical company Boehringer Ingelheim. The deal is one of the largest in Australian biotech history, included significant initial and future payments, and is firm recognition of the Company’s credentials in drug discovery.
In August 2017, Boehringer commenced a phase 2 trial in NASH with BI 1467335, triggering the payment of a development milestone to Pharmaxis of A$27 million.
In September 2017, Boehringer Ingelheim announced it was initiating a phase 2 trial in diabetic retinopathy with BI 1467335. When the first patient is dosed it will trigger the payment of a development milestone to Pharmaxis of A$15 million.
Other amine oxidase drug development programs currently being investigated by Pharmaxis include:
- Selective LOXL2 inhibitor for pulmonary fibrosis
- Selective LOXL2 inhibitor for NASH, liver and kidney fibrosis
- Mixed LOXL inhibitor: scaring and cancer
- SSAO/MPO inhibitor for respiratory and cardiovascular inflammation
In August 2015 Pharmaxis announced a research collaboration with Synairgen plc to develop a LOXL2 inhibitor for pulmonary fibrosis. Pharmaxis expects to enter other collaborations to accelerate some of these programs while retaining others to develop independently.
The Pharmaxis product pipeline also includes: